Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Professor Alistair Burns, Emeritus Professor of Old Age Psychiatry at the University of Manchester and previously England’s National Clinical Director for Dementia, observed, "We have reached an exciting time in the field of Alzheimer’s disease treatment. After no new therapies for a generation, we are on the threshold of having a range of new treatments, including a tau-targeted oral therapy, which have the real potential to slow the disease process. This is great news for people with Alzheimer's disease, their families and carers. "
In light of data shared, HMTM has prospective broad applicability for a wide demographic contributing to equity of access to new treatment options. TauRx has initiated regulatory engagement in the UK and the US for intended product approval. Other territories will follow in line with plans to scale commercialisation of HMTM.
看完一堆看不懂的；
结尾：
Professor Alistair Burns, Emeritus Professor of Old Age Psychiatry at the University of Manchester and previously England’s National Clinical Director for Dementia, observed, "We have reached an exciting time in the field of Alzheimer’s disease treatment. After no new therapies for a generation, we are on the threshold of having a range of new treatments, including a tau-targeted oral therapy, which have the real potential to slow the disease process. This is great news for people with Alzheimer's disease, their families and carers. "
In light of data shared, HMTM has prospective broad applicability for a wide demographic contributing to equity of access to new treatment options. TauRx has initiated regulatory engagement in the UK and the US for intended product approval. Other territories will follow in line with plans to scale commercialisation of HMTM.